1
|
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
|
J Clin Oncol
|
1992
|
1.55
|
2
|
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.
|
J Clin Oncol
|
1992
|
0.92
|
3
|
Biostatistical considerations for quality assessment of immunologic measurements used in clinical and longitudinal studies.
|
Clin Immunol Immunopathol
|
1989
|
0.84
|
4
|
Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
|
Leukemia
|
1992
|
0.75
|
5
|
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076).
|
J Natl Cancer Inst Monogr
|
1992
|
0.75
|
6
|
Chemotherapy versus observation in high-risk node-negative breast cancer patients.
|
J Natl Cancer Inst Monogr
|
1992
|
0.75
|